TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00963313

Intervention type: DRUG
Intervention: Adalimumab (HUMIRA®)
Description: Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
Study: NCT03869164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ValveClamp
Description: ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
Study: NCT04326881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: single dosing
Study: NCT02541019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 75 mcg IV, one minute before the anesthesia induction.
Study: NCT04243681

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD 34 and MSC infusion
Description: Combination of stem cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for Cirrhosis management
Description: Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
Study: NCT04326881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: single dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: single dosing
Study: NCT00722475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Intravenous infusions, 25-35 g each time, 4th to 15th gestational week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human albumin
Description: Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
Study: NCT02868099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00056550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Antithrombin (rhAT)
Description: Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
Study: NCT02390609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment D)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment D)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment D)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment D)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment E)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment E)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment E)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment E)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment F)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment F)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment F)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment F)
Description: Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
Study: NCT00724048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR16
Description: ACR16 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR16
Description: ACR16 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR16
Description: ACR16 will be administered per dose and schedule specified in the arm description.
Study: NCT03064997

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synergy 1
Description: a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
Study: NCT01609374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M6-C Artificial Cervical Disc
Description: Total disc replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior plate system with corticocancellous allograft bone
Description: Cervical fusion
Study: NCT04640285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Cigarette
Description: Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Cigarette
Description: Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Cigarette
Description: Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Cigarette
Description: Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicorette White Ice Mint nicotine polacrilex gum
Description: Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
Study: NCT00724048

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ACR16 will be administered per schedule specified in the arm description.
Study: NCT03333590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MCK.GALGT2
Description: Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
Study: NCT04640285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicorette White Ice Mint nicotine polacrilex gum
Description: Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicorette White Ice Mint nicotine polacrilex gum
Description: Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicorette White Ice Mint nicotine polacrilex gum
Description: Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
Study: NCT00730405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albaconazole 100mg
Description: Albaconazole for 36 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albaconazole 200mg
Description: Albaconazole for 36 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albaconazole 400mg
Description: Albaconazole for 36 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albaconazole 400mg
Description: Albaconazole for 24 weeks, Placebo for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 400 mg
Description: Placebo for 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 400 mg
Description: Placebo for 36 weeks
Study: NCT03598530

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
Study: NCT00796198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan+Cosopt
Description: Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: Xalatan ophthalmic solution one drop at 10pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: Xalatan ophthalmic solution one drop at 10pm
Study: NCT02627105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beef group
Description: Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-beef group
Description: Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
Study: NCT01004705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),
Description: A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: A once daily oral dose of simvastatin for 12 weeks.
Study: NCT03937297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six Arts
Description: The Six Arts intervention is a 24 session, twice a week intervention protocol. There will be four sessions per Art, with specific sequence designed to enhance group dynamic and create harmony. Each session starts with a 15 minutes warm-up exercise, followed by the Six Art theme activity. The program design emphasizes on integrated cognitive, physical, and social activities covering all domains of Six Arts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Description: The CST to be used involve 24 sessions of theme activities, twice a weekly intervention protocol. It is modified into CST-Hong Kong for activities that are not applicable in Hong Kong Chinese culture (e.g. word games involving alphabets)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: usual dementia care provided by participating center
Study: NCT00944905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1203
Description: Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
Study: NCT01496807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sylatron
Description: Sylatron - Once per week for 12 weeks, given as an injection under the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yervoy
Description: Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
Study: NCT01755078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer HCl
Description: Non-metal phosphate binder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium-based phosphate binder
Study: NCT02664389

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Sequencing of 200 selected genes in the different study populations

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Sequencing of 200 selected genes in the different study populations

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Sequencing of 200 selected genes in the different study populations

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Sequencing of 200 selected genes in the different study populations

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Sequencing of 200 selected genes in the different study populations
Study: NCT00978133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermabond ProPen (2-octylcyanoacrylate)
Description: Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin closure with skin staples
Description: Skin closure with skin staples
Study: NCT02939313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medial prefrontal cortex
Description: a form of theta burst stimulation that noninvasively induces a depression in brain reactivity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dorsolateral prefrontal cortex
Description: a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham stimulation
Study: NCT01802268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conversion from Tacrolimus to Sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance on tacrolimus
Study: NCT00533351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN201781
Description: AGN201781 50 mg capsules three-times daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 50 mg capsules three-times daily for 2 weeks
Study: NCT04347616

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UCB-NK cells
Description: Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UCB-NK cells
Description: Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB-NK cells
Description: Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2
Description: In vivo cytokine support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2
Description: In vivo cytokine support
Study: NCT02047968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wake therapy
Study: NCT01518634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Description: Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
Study: NCT04882904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimyo°
Description: Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Study: NCT00558233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHOICE decision aid
Description: computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
Study: NCT01537393

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cornea tissue transplant
Description: Cornea tissue preserved 0 to 7 days

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cornea tissue transplant
Description: Cornea tissue preserved 8 to 14 days.
Study: NCT02893670

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation
Description: All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker.
Study: NCT00561808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-vitro maturation oocytes
Description: Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
Study: NCT02516163

Intervention type: DEVICE
Group type: OTHER
Intervention: Shapematch Cutting Guides
Description: Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
Study: NCT04589078

Intervention type: DEVICE
Intervention: GI Genius CADe system
Description: Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
Study: NCT03760783

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Description: Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
Study: NCT04193332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR optical imaging camera
Description: NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
Study: NCT02609269

Intervention type: OTHER
Intervention: Decipher Cancer Classifier
Description: The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA
Study: NCT04211623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constraint induced movement therapy
Description: Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~* 10 degrees active wrist extension on the affected hand,~* 10 degrees active thumb abduction,~* 10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~* using fork or a spoon,~* combing hair~* brushing teeth~* writing~* dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bimanual activities
Description: Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~* carrying a tray,~* cutting a fruit with a knife,~* holding and cutting the paper with scissor,~* buttoning and~* Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session.